AR052221A1 - Metodo para el tratamiento de la enfermedad poliquistosis renal - Google Patents

Metodo para el tratamiento de la enfermedad poliquistosis renal

Info

Publication number
AR052221A1
AR052221A1 ARP050104236A ARP050104236A AR052221A1 AR 052221 A1 AR052221 A1 AR 052221A1 AR P050104236 A ARP050104236 A AR P050104236A AR P050104236 A ARP050104236 A AR P050104236A AR 052221 A1 AR052221 A1 AR 052221A1
Authority
AR
Argentina
Prior art keywords
inhibitor
src
treatment
mammal
disease
Prior art date
Application number
ARP050104236A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR052221A1 publication Critical patent/AR052221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP050104236A 2004-10-08 2005-10-07 Metodo para el tratamiento de la enfermedad poliquistosis renal AR052221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61698104P 2004-10-08 2004-10-08

Publications (1)

Publication Number Publication Date
AR052221A1 true AR052221A1 (es) 2007-03-07

Family

ID=36013658

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104236A AR052221A1 (es) 2004-10-08 2005-10-07 Metodo para el tratamiento de la enfermedad poliquistosis renal

Country Status (12)

Country Link
US (1) US20060079515A1 (https=)
EP (1) EP1796727A2 (https=)
JP (1) JP2008515913A (https=)
CN (1) CN101102757A (https=)
AR (1) AR052221A1 (https=)
AU (1) AU2005294258A1 (https=)
BR (1) BRPI0516533A (https=)
CA (1) CA2580864A1 (https=)
MX (1) MX2007004001A (https=)
PE (1) PE20060681A1 (https=)
TW (1) TW200616612A (https=)
WO (1) WO2006042100A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
CN103313713B (zh) 2010-08-26 2014-12-31 和谐进化股份有限公司 受体型激酶调节剂和多囊性肾病的治疗方法
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
PL370137A1 (en) * 2001-11-27 2005-05-16 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Also Published As

Publication number Publication date
EP1796727A2 (en) 2007-06-20
US20060079515A1 (en) 2006-04-13
PE20060681A1 (es) 2006-08-28
CA2580864A1 (en) 2006-04-20
CN101102757A (zh) 2008-01-09
JP2008515913A (ja) 2008-05-15
WO2006042100A3 (en) 2007-06-07
MX2007004001A (es) 2007-05-11
TW200616612A (en) 2006-06-01
BRPI0516533A (pt) 2008-09-09
WO2006042100A2 (en) 2006-04-20
AU2005294258A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
CL2008003298A1 (es) Forma de dosificacion oral solida que comprende a) un compuesto de accion doble en concentracion entre 4 y 90%, b) un excipiente farmaceuticamente aceptable; proceso de preparación; uso en el tratamiento de enfermedades cardiovasculares y/o renales.
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
CO6160236A2 (es) Inhibidor de quinasa
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
CO5680428A2 (es) Antagonistas del receptor de trombina
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR029763A1 (es) Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento
MX2009010289A (es) Composiciones para administracion nasal.
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
GT200900142A (es) Combinacion de los inhibidores iap y flt3 inhibidores
AR109263A2 (es) Composición que comprende moxidectina
CR8220A (es) Composicion de fexofenadina y proceso para su preparacion
BR0308108A (pt) Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
CR10253A (es) "inhibidores de pai-1 para tratamiento de afecciones musculares"
AR054806A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
AR056014A1 (es) Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal